162 related articles for article (PubMed ID: 11221831)
1. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy.
Hambek M; Solbach C; Schnuerch HG; Roller M; Stegmueller M; Sterner-Kock A; Kiefer J; Knecht R
Cancer Res; 2001 Feb; 61(3):1045-9. PubMed ID: 11221831
[TBL] [Abstract][Full Text] [Related]
2. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
[TBL] [Abstract][Full Text] [Related]
5. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
[TBL] [Abstract][Full Text] [Related]
6. Cancer of the uterine cervix is susceptible to anti-EGF-R antibody EMD 55,900 therapy.
Solbach C; Roller M; Nicolettri M; Budischewski K; Knecht R; Kaufmann M
Anticancer Res; 2005; 25(6B):4261-7. PubMed ID: 16309226
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
8. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
Fan Z; Baselga J; Masui H; Mendelsohn J
Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640
[TBL] [Abstract][Full Text] [Related]
11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha.
Fong CJ; Sherwood ER; Mendelsohn J; Lee C; Kozlowski JM
Cancer Res; 1992 Nov; 52(21):5887-92. PubMed ID: 1394216
[TBL] [Abstract][Full Text] [Related]
13. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
[TBL] [Abstract][Full Text] [Related]
14. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas.
Ma D; Niederkorn JY
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1067-75. PubMed ID: 9620065
[TBL] [Abstract][Full Text] [Related]
15. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
[TBL] [Abstract][Full Text] [Related]
16. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
17. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
18. Dependence of a human squamous carcinoma and associated paraneoplastic syndromes on the epidermal growth factor receptor pathway in nude mice.
Yoneda T; Alsina MM; Watatani K; Bellot F; Schlessinger J; Mundy GR
Cancer Res; 1991 May; 51(9):2438-43. PubMed ID: 2015605
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
20. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
